Inhibitory effects of Solidago chilensis Meyen hydroalcoholic extract on acute inflammation.
OBJECTIVE
Alcoholic or hydroalcoholic preparations of the plant Solidago chilensis Meyen (Asteraceae) are employed in popular medicines to treat inflammation. The anti-inflammatory effects of the hydroalcoholic extract of aerial parts of the plant (93% ethanol) were investigated and the main components of the extract were identified.


METHODS
Ear oedema was induced in male Wistar rats by topical application of the chloroform fraction of latex-extract from Euphorbia milii. Leukocyte mobilisation was quantified after air-pouch inflammation evoked by oyster glycogen. Leukocyte-endothelial interactions and mast cell degranulation were quantified by intravital microscopy. The extract itself was characterised via HPLC-DAD-MS and HPLC-MS/MS.


RESULTS
Topical (12.5-50mg/kg) or intraperitoneal (25 or 50mg/kg) administrations of the extract reduced ear oedema formation (>25% reduction). Intraperitoneal applications of 25mg/kg of extract inhibited the migration of polymorphonuclear cells into the inflamed cavity (about 50%). In addition, the rolling behaviour and adherence of circulating leukocytes to postcapillary venules of the mesentery network was diminished (50%), but the mast cell degranulation in the perivascular area was not affected. The major components of the extract were identified as caffeoylquinic acid derivatives and the flavonoid rutin.


CONCLUSIONS
The data presented herein show local and systemic anti-inflammatory effects of the hydroalcoholic extract of aerial parts of Solidago chilensis, and implicate the inhibition of leukocyte-endothelial interactions as an important mechanism of the extract's action.
Tamura
Eduardo Koji
EK
Area de Ciências da Saúde, Universidade Braz Cubas, Mogi das Cruzes, SP, Brazil.
Jimenez
Renata Spada
RS
Waismam
Kaline
K
Gobbo-Neto
Leonardo
L
Lopes
Norberto Peporine
NP
Malpezzi-Marinho
Elena A L
EA
Marinho
Eduardo A V
EA
Farsky
Sandra H P
SH
D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D004727:Endothelium / Q000187:drug effects; D007274:Injections, Intraperitoneal; D007962:Leukocytes / Q000187:drug effects*; D008297:Male; D008407:Mast Cells / Q000187:drug effects*; D008517:Phytotherapy; D035261:Plant Components, Aerial; D010936:Plant Extracts / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D011801:Quinic Acid / Q000031:analogs & derivatives / Q000302:isolation & purification / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012431:Rutin / Q000302:isolation & purification / Q000494:pharmacology; D036624:Solidago
D000893:Anti-Inflammatory Agents; D010936:Plant Extracts; C472707:caffeoylquinic acid; D011801:Quinic Acid; D012431:Rutin